| Edurant (rilpivirine) / J&J |
2012-002663-10: Darunavir/ritonavir and rilpivirine in therapy-naïve patients. |
|
|
| Completed | 4 | 40 | Europe | Edurant (rilpivirine), Prezista (darunavir), Norvir (ritonavir), Film-coated tablet, Edurant, Prezista, Norvir | St Stephen's AIDS Trust, Janssen-Cilag Ltd | HIV-1, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
ChiCTR-TRC-14004908: Rilpivirine Versus Efavirenz with Tenofovir and lamivudine's use in treatment-naive adults with HIV-1 infection and injection drug use on Methadone maintenance treatment |
|
|
| Recruiting | 4 | 60 | | taking Rilpivirine RPV+TDF+3TC and methadone ;taking Rilpivirine RPV+TDF+3TC and methadone | Yunnan Provincial Infectious Disease Hospital; Yunnan Provincial Infectious Disease Hospital, Funded by Xian Janssen Pharmaceutical Ltd. | AIDS | | | | |
2014-002284-15: A study to assess changes in Central Nervous System (CNS) function where no obvious symptoms exist, when switching from Atripla to Eviplera switch in HIV infected patients |
|
|
| Completed | 4 | 40 | Europe | Eviplera, Film-coated tablet, Eviplera | St Stephen's AIDS Trust, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA. |
|
|
| Completed | 4 | 291 | Europe | Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Film-coated tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ, REZOLSTA, EVOTAZ, GENVOYA | FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA, UNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA, ViiVHealthcare | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq |
|
|
| Completed | 4 | 90 | Europe | Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera | King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd | Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04340388: Contribution of Dolutegravir to Obesity and Cardiovascular Disease |
|
|
| Completed | 4 | 10 | US | Dolutegravir 50 MG, Tenofovir alafenamide, Tenofovir disoproxil fumarate, Abacavir, Lamivudine, Darunavir, Cobicistat, Rilpivirine, Combivir, Zidovudine, Antiretroviral/Anti HIV, Antiretroviral Combinations | Augusta University | HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome | 06/22 | 02/23 | | |
MAFALDA-R, NCT05898841 / 2022-503110-23-00: Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load |
|
|
| Completed | 4 | 63 | Europe | Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. | Fundacion SEIMC-GESIDA | HIV Infections, Fatty Liver Disease | 07/25 | 07/25 | | |
2023-503963-41-00: Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infected patients from Spain. Acceptability, appropriateness, feasibility and satisfaction. The HOLA Study. |
|
|
| Completed | 4 | 110 | Europe | EDURANT 25 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection, Vocabria 30 mg film-coated tablets | Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia, ViiV Healthcare | HIV-Infected patients | | | | |
GESIDA 12422, 2022-503110-23-00: Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load |
|
|
| Completed | 4 | 75 | Europe | Juluca 50 mg/25 mg film-coated tablets, Emtricitabine/Tenofovir disoproxil Tillomed 200 mg/245 mg filmdragerade tabletter, Truvada 200 mg/245 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, Tivicay 50 mg film-coated tablets, Emtricitabina/Tenofovir disoproxilo Aurovitas 200 mg/245 mg comprimidos recubiertos con pel?cula EFG, Odefsey 200 mg/25 mg/25 mg film-coated tablets, EDURANT 25 mg film-coated tablets | Fundacion Seimc Gesida | Metabolic liver disease in HIV-infected people | | | | |
103900, 2024-515487-31-00: Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) |
|
|
| Completed | 4 | 163 | Europe | Ziagen 300 mg film-coated tablets, INTELENCE 200 mg tablets, Eviplera 200 mg/25 mg/245 mg film-coated tablets, EDURANT 25 mg film-coated tablets, Telzir 700 mg film-coated tablets, TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets, Delstrigo 100 mg/300 mg/245 mg film-coated tablets, Norvir 100 mg film-coated tablets, Ritonavir Accord 100 mg filmomhulde tabletten, Descovy 200 mg/10 mg film-coated tablets, REYATAZ?300?mg hard capsules, REKAMBYS 600 mg prolonged-release suspension for injection, Tivicay 50 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Viread 245 mg film-coated tablets, Emtriva 200 mg hard capsules, Descovy 200 mg/25 mg film-coated tablets, CELSENTRI 300 mg film-coated tablets, Truvada 200 mg/245 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Odefsey 200 mg/25 mg/25 mg film-coated tablets, STOCRIN 600 mg film-coated tablets, Vocabria 400 mg prolonged-release suspension for injection, INTELENCE 100 mg tablets, Aptivus 250?mg soft capsules, Pifeltro 100 mg film-coated tablets, CELSENTRI 150 mg film-coated tablets, Kivexa 600 mg/300 mg film-coated tablets, ISENTRESS 400 mg film-coated tablets, Fuzeon 90 mg/ml powder and solvent for solution for injection, Vocabria 600 mg prolonged-release suspension for injection, ISENTRESS 600 mg film-coated tablets | Stichting Radboud universitair medisch centrum | HIV-infected | | | | |
2013-002573-22: PROBE TRIAL proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucleosidic backbone in virologic suppressed patients STUDIO PROBE rivolto a pazienti con infezione da HIV tratatti con una combinazioen di tre farmaci( due nucleosidici ed un inibitore della proteasi) e che presentano una risposta ottimale con mancata replicazione stabile del virus HIV |
|
|
| Ongoing | 3 | 60 | Europe | Coated tablet, Edurant, Prezista, Norvir | A.O PAPA GIOVANNI XXIII- BERGAMO, janssen | HIV1-infected adults pazienti con infezione HIV, HIV1-infected adults of ≥ 18 years of age on an effective ARV therapy (HIV-RNA < 50 copies/ml) based on the use of two NRTIs and a boosted-PI Adulti con infezione da HIV1 di età ≥ 18 anni con un efficace terapia ARV (HIV-RNA <50 copie / ml), basato sull'utilizzo di due NRTI e un potenziato-PI, Diseases [C] - Immune System Diseases [C20] | | | | |
2014-003419-12: Switch from Efavirenz/Atripla to Rilpivirine Switch da Efavirenz/Atripla a Rilpivirina |
|
|
| Terminated | 3 | 90 | Europe | EVIPLERA, ATRIPLA, Capsule, hard, EVIPLERA, ATRIPLA | AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA, Gilead Sciences Srl | HIV INFECTION INFEZIONE DA HIV, HIV HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2016-002413-22: Open label, Randomized clinical trial to evaluate switching from dual regimens to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients Studio in aperto, randomizzato, per valutare il passaggio da una terapia duplice ad una terapia con E/C/F/TAF in pazienti adulti HIV positivi con carica virale negativa. |
|
|
| Terminated | 3 | 100 | Europe | Tivicay (dolutegravir), Emtriva, Lamivudina, Viread, Ziagen, Edurant, Intelence, Sustiva, Viramune, Film-coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Genvoya¿ 150 mg/150mg/200mg/10mg, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EMTRIVA - 30 CAPSULE RIGIDE IN BLISTER DA 200 MG, LAMIVUDINA MYLAN - 300 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/PVDC/AL, VIREAD - 245 MG 30 COMPRESSE RIVESTITE CON FILM IN FLACONE USO ORALE, ZIAGEN - 300 MG COMPRESSE FILMRIVESTITE 6 BLISTER 10 COMPRESSE USO ORALE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE, SUSTIVA - 600 MG COMPRESSE FILM RIVESTITE 1 FLACONE 30 COMPRESSE USO ORALE, VIRAMUNE - 400 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - BLISTER (PVC/AL) 30 COMPRESSE | OSPEDALE SAN RAFFAELE, Gilead Sciences Inc. | HIV infection Infezione da HIV, HIV infected subjects pazienti affetti da virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2016-003948-36: A pilot study to evaluate the use of rilpivirine plus darunavir / cobicistat as substitute agents in virologic suppressed patients Studio pilota per valutare l'uso di rilpivirina più darunavir / cobicistat come agenti sostitutivi nei pazienti con carica virologica soppressa |
|
|
| Completed | 3 | 160 | Europe | darunavir+cobicistat, rilpivirina, Film-coated tablet, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE | AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII, Janseen- Cilag S.p.A | HIV-1 infection on an effective ARV therapy (HIV-RNA < copies/ml) pazienti con infezione HIV-1 virologicamente soppressi, HIV-1 infection pazienti HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2020-003951-13: Dual therapy in HIV patients in 4 days a week versus 7 days a week Bithérapie chez des patients HIV en 4 jours sur 7 versus 7 jours sur 7 |
|
|
| Completed | 3 | 440 | Europe | Film-coated tablet, TIVICAY, EPIVIR, PREZISTA, EDURANT, NORVIR | INSERM-ANRS, ANRS | HIV infection Infection par le VIH, HIV infection Infection par le VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2022-001437-36: ITACO study and the Analytical Antiretroviral Treatment Interruption study (ITACO-ATI) Studio ITACO e studio sull'interruzione del Trattamento Antiretrovirale (ITACO-ATI) |
|
|
| Not yet recruiting | 3 | 61 | Europe | ODEFSEY, REZOLSTA, BIKTARVY, Triumeq, Edurant, Tivicay, Descovy, Symtuza, Dovato, Epivir, [na], Film-coated tablet, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, Biktarvy, TRIUMEQ - 50MG/600MG/300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE HDPE - 1 FLACONE 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, Symtuza, DOVATO - 50 MG / 300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EPIVIR - 300 MG 1 FLACONE 30 COMPRESSE RIVESTITE CON FILM USO ORALE | IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, NIH (Johns Hopkins University) | perinatally HIV infection Infezione da HIV perinatale, perinatally HIV infection Infezione da HIV perinatale, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05896761: A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants |
|
|
| Completed | 3 | 118 | Europe, Canada, US, RoW | Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension | ViiV Healthcare, Janssen Research and Development | Human Immunodeficiency Virus Type 1 (HIV-1) | 08/22 | 08/22 | | |
2021-000243-50: Understanding the Impact of HIV-DNA resistance mutations detected by NGS in Simplificationstrategies to 2-Drug Regimens for patients virologically suppressed with previous failures and/orprevious resistance mutations: a prospective multi-centre intervention study (INS-2DR) Impatto delle mutazioni di resistenza rilevate su HIV-DNA con NGS nelle strategie di Semplificazione a regimi a due farmaci in pazienti HIV+ virologicamente soppressi con pregressi fallimenti virologici e/o pregresse mutazioni di resistenza: uno studio prospettico interventistico multi-centrico (INS-2DR) |
|
|
| Terminated | 3 | 210 | Europe | Lamivudina, Pifeltro, Emtriva, Juluca, Janssen-Cilag International NV, Tivicay, Dovato, [-], Tablet, Film-coated tablet, Capsule, hard, Coated tablet, Lamivudina, Pifeltro, Emtriva, Juluca, EDURANT, Tivicay, Dovato | ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI", Ministero della salute | HIV infection Infezione da HIV, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
LATTE-2, NCT02120352 / 2013-000783-29: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects |
|
|
| Completed | 2 | 309 | Europe, Canada, US | CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV | ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline | Infection, Human Immunodeficiency Virus, HIV Infections | 08/15 | 04/23 | | |
NCT04012931 / 2018-004301-32: A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed |
|
|
| Completed | 2 | 26 | Europe, RoW | Rilpivirine, TMC278, ARV Background Regimen | Janssen Research & Development, LLC, Janssen Sciences Ireland Unlimited Company, Janssen Sciences Ireland UC | HIV | 02/23 | 02/23 | | |
2022-000829-24: Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1 |
|
|
| Not yet recruiting | 2 | 20 | US | JULUCA, J05AR21, Tablet, (GSK3365791 (GSK1349572+GSK1329758); JULUCA (Dolutegravir 50 mg and Rilpivirine 25 mg Fixed Dose Combination Tablet) | ViiV Healthcare UK Limited, ViiV Healthcare, Janssen Research and Development | Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1, HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
| Withdrawn | 2 | 40 | US | Combined LAI Treatment: Cabenuva and Sublocade, rilpivirine (CAB/RPV) "cabenuva", extended-release buprenorphine (XR-B) "sublocade" | Rhode Island Hospital | Human Immunodeficiency Virus, Opioid Use Disorder | 08/25 | 02/26 | | |
NCT07637877: Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study |
|
|
| Recruiting | 2 | 21 | RoW | cART + Rilpivirine, cART | Beijing 302 Hospital, Shenzhen Third People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou Eighth People's Hospital | Immunological Non-Responders in People With HIV | 12/28 | 01/29 | | |
| Completed | 2 | 48 | Europe, RoW | Rilpivirine, TMC278, R278474 | Janssen Sciences Ireland UC | Human Immunodeficiency Virus Type 1 | 08/26 | 08/26 | | |
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents |
|
|
| Completed | 1/2 | 168 | US, RoW | Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART) | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 02/23 | 04/25 | | |
| Not yet recruiting | 1/2 | 155 | RoW, US | Cabotegravir LA, Cabotegravir, Rilpivirine, Rilpivirine LA, Suspension for injection, Tablet | National Institute of Allergy and Infectious Diseases, Division of AIDS, ViiV Healthcare UK Limited, Janssen Sciences Ireland UC | HIV-1, HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2024-512889-33-00: A roll-over study with rilpivirine for human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies. |
|
|
| Active, not recruiting | 1/2 | 3 | Europe | RILPIVIRINE
, JNJ-16150108 | Janssen Sciences Ireland Unlimited Company | HIV-1 Infection | | | | |
NCT07001488: A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV) |
|
|
| Completed | 1 | 15 | RoW | Azvudine tablets(FNC) and Rilpivirine Tablets (RPV), Azvudine tablets (FNC) and Rilpivirine Tablets (RPV) | Henan Genuine Biotech Co., Ltd. | Healthy | 05/22 | 01/23 | | |
CTR20213136: Clinical study on the interaction between azvudine tablets (FNC) and rilpivirine tablets (RPV) |
|
|
| Completed | 1 | 15 | China | 1. Chinese Generic Name: Azvudine Tablets; English Generic Name: Azvudine; Brand Name: NA;
2. Chinese Generic Name: Azvudine Tablets; English Generic Name: Azvudine; Brand Name: Shuangxin Aike;
3. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Enlin | Beijing Union Medical College Pharmaceutical Factory / Henan Zhenshi Biotechnology Co., Ltd. | Indications: For the treatment of patients infected with Human Immunodeficiency Virus (HIV). | | | | |
CTR20200828: Human bioequivalence study of rilpivirine tablets |
|
|
| Not yet recruiting | N/A | 16 | China | 1. Chinese Generic Name: Rilpivirine Tablets; 2. Chinese Generic Name: Rilpivirine Tablets; 1. Chinese Generic Name: Rilpivirine Tablets English Name: Rilpivirine Tablets Brand Name: Edurant | Chengdu Better Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
CTR20201589: Human bioequivalence study of rilpivirine tablets |
|
|
| Not yet recruiting | N/A | 80 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Edurant | Chengdu Better Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
UMIN000019659: A pilot study to evaluate efficacy and safety of sofosbuvir and daclatasvir for HCV genotype 3 infection in HIV and HCV co-infected hemophiliacs |
|
|
| Completed | N/A | 4 | Japan | Patients receive sofosbuvir 400mg plus daclatasvir 60mg once daily for 12 weeks. In patients receiving antiretroviral therapy with protease inhibitor plus booster, dose of daclatasvir is adjusted to 30mg. In patients receiving antiretroviral therapy with non-nucleic acid reverse transcriptase inhibitor except for rilpivirine, dose of daclatasvir is adjusted to 90mg. | National center for global health and medicine, National center for global health and medicine | HIV infection, AIDS, Chronic hepatitis C infection | | | | |
CTR20211288: A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study evaluating rilpivirine tablets in fasting/postprandial healthy subjects. |
|
|
| Recruiting | N/A | 96 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Enlin? | Qilu Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
CTR20231478: A randomized, open-label, two-period, two-sequence self-crossover design study evaluating the bioequivalence of a single oral dose of rilpivirine tablets in healthy adults under fasting or postprandial conditions. |
|
|
| Terminated | N/A | 98 | | 1. Chinese Generic Name: Lipiverine Tablets; English Generic Name: Lipiverine Tablets; Brand Name: NA; 1. Chinese Generic Name: Lipiverine Tablets; English Generic Name: Lipiverine Tablets; Brand Name: Edurant? | Shanghai Desano Biopharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients aged 12 years and older with a weight of at least 35 kg who have HIV-1 infection at the start of treatment and whose plasma HIV-1 RNA is less than or equal to 100,000 copies/mL. | | | | |
CTR20261508: Postprandial bioequivalence study of emtricitabine tablets in healthy subjects |
|
|
| Not yet recruiting | N/A | 44 | China | 1. Chinese Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; Brand Name: NA; 1. Chinese Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Tablets; Brand Name: ODEFSEY? | Chengdu Better Pharmaceutical Co., Ltd. | Indications: HIV-1 infected patients | | | | |
CTR20210377: Human bioequivalence study of rilpivirine tablets |
|
|
| Completed | N/A | 80 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Edurant | Chengdu Better Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients with HIV-1 infection at the onset of infection, whose HIV-1 RNA levels are less than or equal to 100,000 copies/mL. | | | | |
NCT06405464: Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures |
|
|
| Recruiting | N/A | 600 | Europe | VOCABRIA 30Mg Tablet, Cabotegravir Tablets, EDURANT 25Mg Tablet, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Vocabria, Rilpivirine Injectable Suspension, Rekambys, Intact proviral DNA assay, Full-length sequencing | University of Zurich, Swiss HIV Cohort Study | HIV Infections | 12/25 | 06/26 | | |
| Completed | N/A | 65 | Europe | Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir | Assistance Publique - Hôpitaux de Paris, URC-CIC Paris Descartes Necker Cochin | Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed | 06/22 | 06/22 | | |
CTR20220940: Human bioequivalence study of rilpivirine tablets |
|
|
| Completed | N/A | 96 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Enlin? | Ruiyang Pharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients aged 12 years and older with a weight of at least 35 kg who have HIV-1 infection at the start of treatment and whose plasma HIV-1 RNA is less than or equal to 100,000 copies/mL. | | | | |
CTR20220535: Human bioequivalence study of emtricitabine, rilpivirine, acetaminophen, and tenofovir tablets |
|
|
| Completed | N/A | 80 | China | 1. Chinese Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; Brand Name: NA; 1. Chinese Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; English Generic Name: Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Tablets; Brand Name: ODEFSEY? | Qilu Pharmaceutical Co., Ltd. | Indications: For the treatment of adult patients and children weighing ?35 kg with HIV-1 infection. | | | | |
CTR20222217: Human bioequivalence study of rilpivirine tablets (25 mg) |
|
|
| Completed | N/A | 96 | China | 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: NA; 1. Chinese Generic Name: Rilpivirine Tablets; English Generic Name: Rilpivirine Tablets; Brand Name: Edurant?/??? | Anhui Baker Biopharmaceutical Co., Ltd. | Indications: This product, when used in combination with other antiretroviral drugs, is indicated for the treatment of treatment-na?ve patients aged 12 years and older with a weight of at least 35 kg who have HIV-1 infection at the start of treatment and whose plasma HIV-1 RNA is less than or equal to 100,000 copies/mL. | | | | |
COMBINE-2, NCT04019873: '': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor |
|
|
| Completed | N/A | 774 | Europe | Dolutegravir (DTG), Lamivudine (3TC), Rilpivirine (RPV) | ViiV Healthcare | HIV Infections | 04/23 | 12/23 | | |
CTR20230945: Human bioequivalence study of dolutegravir/rilpivirine tablets |
|
|
| Completed | N/A | 72 | China | 1. Chinese Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; English Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; Brand Name: NA; 1. Chinese Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; English Generic Name: Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets; Brand Name: JULUCA? | Qilu Pharmaceutical Co., Ltd. | Indications: Treatment of adult human immunodeficiency virus type 1 (HIV-1) infection. | | | | |
| Not yet recruiting | N/A | 280 | NA | Cabotegravir, Rilpivirine Drug Combination | University Paris 7 - Denis Diderot, Hopital Foch | Quality of Life | 04/26 | 10/26 | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich. |
|
|
| Recruiting | N/A | 800 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 12/28 | 12/28 | | |
NCT06704204: Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community |
|
|
| Not yet recruiting | N/A | 20 | NA | The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks | The Miriam Hospital, National Institute on Drug Abuse (NIDA) | HIV | 07/25 | 07/25 | | |
NCT07080138: Research on the Psychological Status of Patients With HIV-1 Infection |
|
|
| Not yet recruiting | N/A | 500 | NA | All kinds of INSTI medications, Bictegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Dolutegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Abacavir/Dolutegravir/Lamivudine, Albuvirtide, Dolutegravir, Dolutegravir/Lamivudine, Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Fumarate, Emtricitabine/Tenofovir, Emtricitabine/Tenofovir alafenamide Fumarate, Enovirin, Lamivudine/Zidovudine, Raltegravir, Rilpivirine, All kinds of conventional medications, Abacavir, Efavirenz, Emtricitabine, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Tenofovir, Tenofovir alafenamide Fumarate, Zidovudine | Shanxi Bethune Hospital | HIV-1-infection, Anxiety Depression | 07/26 | 12/26 | | |
